Actelion Gets Early Benefits From Savings Plan, Awaits Opsumit Decision
This article was originally published in The Pink Sheet Daily
With a cost-saving initiative boosting earnings now rather than in 2014 there may be even greater pressure on Actelion’s next-generation PAH therapy – which has a PDUFA date of Oct. 19 – to replace the Swiss company’s aging top-selling product, Tracleer.
You may also be interested in...
Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.
European Pharma In Cost-Cutting Mode: Actelion Axes 135 Positions, Sanofi Aims At French R&D Consolidation
Europe's leading biotech Actelion plans to cut 5% of its workforce, while Sanofi considers a major overhaul of its R&D sites in France, as competitive pressures and the European debt crisis continue.
Germany’s Boehringer Ingelheim highlighted its clinical-stage research efforts in neuropsychiatry and COVID-19 when describing its first half financial results as solid, despite the continuing impact of the pandemic.